GlassScriptPhysician profile
Joseph Michael Rios
NPI 1487194742
$20,387.42
in general payments reported to CMS, 2019-2025
30 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.71 · 2020: $30.39 · 2021: $250 · 2022: $7,894 · 2023: $11K · 2024: $848 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $2,004 · Travel and Lodging: $96.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,093.75 |
| Food and Beverage | $2,004.00 |
| Travel and Lodging | $96.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,544.39 | 2021-2025 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $274.98 | 2024-2025 | General - Therapies |
| Lundbeck LLC | $182.35 | 2024-2025 | Vyepti |
| Nevro Corp. | $149.75 | 2022-2023 | Senza |
| Genentech USA, INC. | $126.98 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Scilex Pharmaceuticals INC. | $108.89 | 2021-2022 | |
| Amgen INC. | $96.23 | 2021-2022 | |
| Allergan, INC. | $95.36 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.04 | 2022-2025 | Hyqvia |
| Pfizer INC. | $68.56 | 2023-2024 | |
| Eisai INC. | $66.72 | 2024 | |
| Mdd US Operations, LLC | $59.56 | 2024-2025 | Gocovri |
| Lilly USA, LLC | $57.77 | 2023-2024 | Emgality, Reyvow, Amyvid |
| Neurocrine Biosciences, INC. | $56.57 | 2020-2024 | Ingrezza |
| Sk Life Science, INC. | $53.98 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $51.79 | 2022 | |
| Amneal Pharmaceuticals LLC | $42.08 | 2024 | Crexont, Rytary |
| Argenx US, INC. | $33.29 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $32.60 | 2021-2023 | Spinraza |
| Novartis Pharmaceuticals Corporation | $25.91 | 2024 | |
| Tg Therapeutics, INC. | $24.95 | 2024 | |
| Ge Healthcare | $24.79 | 2022 | |
| Mallinckrodt Hospital Products INC. | $22.62 | 2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $21.78 | 2022 | |
| Kyowa Kirin, INC. | $17.71 | 2019 | |
| Abbott Laboratories | $15.75 | 2023 | Proclaim |
| Adamas Pharmaceuticals, INC. | $15.72 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.19 | 2023 | Horizant |
| Idorsia Pharmaceuticals US INC | $13.97 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.14 | 2024 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.